GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts

GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership

Biogen unveils promising new data for Salanersen in kids with SMA

Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains

Aster DM bags overwhelming shareholder backing for merger with Quality Care

The endorsement follows overwhelming support for the share swap preceding the merger,

BioNTech co-founders launch new mRNA venture, aiming to revolutionize next-gen therapies

The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission

Almirall opens Shanghai hub to power dermatology innovation and China partnerships

The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development

Veristat expands global trial & regulatory services as Chinese drugmakers push overseas

The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals

Middle East conflict pushes health systems to brink as casualties, displacement surge: WHO

The conflict is also triggering a widening public health emergency

Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker